BRAF and metastatic neoplasm: RAS mutational status (at time of diagnosis)BRAF mutational status—V600E—(alongside assessment of RAS)MSI testing (in metastatic disease setting)DPD deficiency testing (option)UGT1A1 phenoyping (option)